Class information for:
Level 1: CYTOMEGALOVIRUS//VALGANCICLOVIR//GANCICLOVIR

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
231 3781 29.0 82%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
630 13104 CYTOMEGALOVIRUS//HUMAN CYTOMEGALOVIRUS//HHV 6

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CYTOMEGALOVIRUS Author keyword 159 19% 20% 763
2 VALGANCICLOVIR Author keyword 139 63% 4% 139
3 GANCICLOVIR Author keyword 81 27% 7% 259
4 PREEMPTIVE THERAPY Author keyword 75 72% 2% 59
5 ANTIGENEMIA Author keyword 55 51% 2% 78
6 PP65 ANTIGENEMIA Author keyword 36 79% 1% 23
7 CMV Author keyword 31 17% 4% 163
8 CYTOMEGALOVIRUS INFECTION Author keyword 28 30% 2% 80
9 GANCICLOVIR RESISTANCE Author keyword 23 72% 0% 18
10 PRE EMPTIVE THERAPY Author keyword 22 50% 1% 32

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CYTOMEGALOVIRUS 159 19% 20% 763 Search CYTOMEGALOVIRUS Search CYTOMEGALOVIRUS
2 VALGANCICLOVIR 139 63% 4% 139 Search VALGANCICLOVIR Search VALGANCICLOVIR
3 GANCICLOVIR 81 27% 7% 259 Search GANCICLOVIR Search GANCICLOVIR
4 PREEMPTIVE THERAPY 75 72% 2% 59 Search PREEMPTIVE+THERAPY Search PREEMPTIVE+THERAPY
5 ANTIGENEMIA 55 51% 2% 78 Search ANTIGENEMIA Search ANTIGENEMIA
6 PP65 ANTIGENEMIA 36 79% 1% 23 Search PP65+ANTIGENEMIA Search PP65+ANTIGENEMIA
7 CMV 31 17% 4% 163 Search CMV Search CMV
8 CYTOMEGALOVIRUS INFECTION 28 30% 2% 80 Search CYTOMEGALOVIRUS+INFECTION Search CYTOMEGALOVIRUS+INFECTION
9 GANCICLOVIR RESISTANCE 23 72% 0% 18 Search GANCICLOVIR+RESISTANCE Search GANCICLOVIR+RESISTANCE
10 PRE EMPTIVE THERAPY 22 50% 1% 32 Search PRE+EMPTIVE+THERAPY Search PRE+EMPTIVE+THERAPY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ORAL GANCICLOVIR 303 69% 7% 257
2 PREEMPTIVE THERAPY 198 64% 5% 195
3 GANCICLOVIR 165 28% 13% 499
4 PP65 ANTIGENEMIA 162 73% 3% 123
5 ANTIGENEMIA ASSAY 139 80% 2% 87
6 HIGH DOSE ACYCLOVIR 115 76% 2% 80
7 VALGANCICLOVIR PROPHYLAXIS 110 84% 2% 61
8 CMV DISEASE 109 53% 4% 147
9 GANCICLOVIR PROPHYLAXIS 102 63% 3% 103
10 VALGANCICLOVIR 84 52% 3% 114

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Universal Prophylaxis or Preemptive Strategy for Cytomegalovirus Disease After Liver Transplantation: A Systematic Review and Meta-Analysis 2015 1 60 93%
Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review 2014 15 64 70%
How I treat cytomegalovirus in hematopoietic cell transplant recipients 2009 131 98 76%
Antiviral Drug Resistance of Human Cytomegalovirus 2010 111 203 69%
Infection in organ-transplant recipients 1998 812 67 31%
Medical progress: Infection in solid-organ transplant recipients 2007 479 82 26%
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies 2003 188 89 83%
Quantitation of cytomegalovirus: Methodologic aspects and clinical applications 1998 246 166 83%
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2013 19 141 88%
Antiviral drugs for cytomegalovirus diseases 2006 161 56 59%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 UNIV MED ASSOCIATES 6 100% 0.1% 4
2 HEPATOBILIARY PANCREAT SURG HEPAT TRANSPLANT 4 75% 0.1% 3
3 REFERENCE CMV 4 75% 0.1% 3
4 REFERENCE CYTOMEGALOVIRUS 4 50% 0.2% 6
5 TRANSPLANT INFECT DIS 3 39% 0.2% 7
6 REFERENCE CYTOMEGALOVIRUSES 3 100% 0.1% 3
7 MED VIROL EPIDEMIOL VIRAL DIS 3 21% 0.3% 13
8 HEMATOL MED ONCOL SERV 3 25% 0.2% 9
9 SPERIMENTALI RIC 2 17% 0.3% 12
10 JANE DAYTON BROWN DAYTON T BROWN JR VIROL 2 67% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000196156 CMV SPECIFIC T CELLS//ONCOHEMATOL GRP//CYTOMEGALOVIRUS SPECIFIC T CELLS
2 0.0000122141 CYTOMEGALOVIRUS COLITIS//CYTOMEGALOVIRUS ENTERITIS//CMV COLITIS
3 0.0000110624 CONGENITAL INFECTION//CONGENITAL CYTOMEGALOVIRUS INFECTION//CYTOMEGALOVIRUS
4 0.0000103137 HUMAN CYTOMEGALOVIRUS//HCMV//US28
5 0.0000100805 CYTOMEGALOVIRUS RETINITIS//CMV RETINITIS//IMMUNE RECOVERY UVEITIS
6 0.0000090946 TRANSPLANT MED NEPHROL//GRAM NEGATIVE BACILLUS//SURG NURSING TRANSPLANTAT
7 0.0000068898 MURINE CYTOMEGALOVIRUS//MCMV//LY49H
8 0.0000066288 CMV DNA LOAD//HERPES HEPATITIS//HERPES SIMPLEX VIRUS PNEUMONIA
9 0.0000065722 TADEUSZ ORLOWSKI//MCGOOGAN LIB MED//ANTIBODY REPLACEMENT THERAPY
10 0.0000055020 ACYCLOVIR//9 CARBOXYMETHOXYMETHYLGUANINE//VALACYCLOVIR